Improving selection of individuals into lung cancer screening programmes
Menée aux Etats-Unis auprès de 8 739 patients fumeurs ou anciens fumeurs atteints d'un cancer du poumon diagnostiqué entre 1997 et 2017 (âge : de 50 à 80 ans ; durée médiane de suivi : 6,5 ans), cette étude évalue la survie globale à 5 ans des patients en fonction de leur éligibilité au programme de dépistage du cancer du poumon selon les critères de l'"US Preventive Services Task Force"
The results of the National Lung Screening Trial (NLST), first announced in November, 2010, showed a 20% decline in mortality with three rounds of screening. The NELSON study was presented at the International Association for the Study of Lung Cancer meeting and confirmed the benefit of screening. Work by James Hanley and colleagues utilised the NLST data and showed that continued annual screening could potentially lower mortality by as much as 30%. Current screening guidelines by the US Preventive Services Task Force (USPSTF), Centers for Medicare and Medicaid Services, and many major US medical organisations follow entry criteria similar to that used for the NLST: age 55–80 years, 30 pack-years of smoking, and, for former smokers, those who quit within the past 15 years. The USPSTF guidelines were based on microsimulation modelling from the Cancer Intervention Surveillance Network and a point on their efficacy frontier that resembled the NLST entry criteria but extended the age cutoff to 80 years. Uptake of lung cancer screening is low according to data from the American College of Radiology.
The Lancet Oncology , commentaire, 2018